Product Description
Trotabresib is an orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/118021883)
Mechanisms of Action: BET Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Japan, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: B-Cell Marginal Zone Lymphoma|Basal Cell Carcinoma|Brain Cancer|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Large Cell Carcinoma|Lymphoma|Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT03936465 | P1 |
Completed |
Lymphoma|Brain Cancer |
2024-03-16 |
|
JapicCTI-205272 | P1 |
Active |
B-Cell Marginal Zone Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Large Cell Carcinoma|Basal Cell Carcinoma |
2022-12-31 |